Dose Insider / Analyses / Zepbound maintenance dose

Zepbound Maintenance DoseStaying on 5, 10 or 15 mg, Stepping Down, and How Long Treatment Lasts

Updated November 20, 2026 · 25 min read · FDA label, SURMOUNT-MAINTAIN

The Zepbound label names three maintenance doses: 5, 10 and 15 mg once a week. Which one is a matter of response and tolerability.

16.6%still off a year after stepping down to 5 mg, 21.9% on the full dose
Weight loss held a year laterStep-down trial, share of starting weightStayed on full dose21.9%Stepped down to 5 mg16.6%Stopped9.9%Weight loss held a yearlaterStep-down trial, share of starting weightStayed on full dose21.9%Stepped down to 5 mg16.6%Stopped9.9%

Stepping down to 5 mg held most of the loss; stopping lost more than half of it.

On this page

In the one trial that tested stepping down, people who dropped from 10 or 15 mg to 5 mg held a 16.6% loss a year later, against 21.9% for those who stayed on the higher dose and 9.9% for those who stopped.

This page puts those three outcomes into your own weight. Then it goes through what the label says, what each maintenance dose delivered in the main trial, how many people held their loss on a lower dose, what the three-year data show, and what is and is not known about stretching the time between injections.

What would the next year look like on each path?

Enter your weight before Zepbound and your weight now, on the dose you have settled on. The calculator applies the results of the three groups in the step-down trial to the weight you have lost.

Three paths, one yearLancet 2026
Unit
A year from now, on the trial averages
Stay on 10 or 15 mg · —
Step down to 5 mg · —
Stop · —
Full dose5 mgStopped

Log your weight on the maintenance dose and the app shows the trend against these lines.

Open the app

The numbers along the bottom are weeks from now. The dotted line is your weight before Zepbound. Trial averages after 60 weeks on 10 or 15 mg; lines are drawn straight between today and week 52. A single person can land well away from them.

The calculator opens with the trial's average participant: 251 lb at the start and, after losing 21.9%, 196 lb. A year on 5 mg takes that person to about 209 lb. A year without the drug takes them to about 226 lb. Staying on the full dose keeps them at 196 lb.

The trial behind the numbers

The trial is SURMOUNT-MAINTAIN, published in the Lancet in 2026. It ran at 20 sites in the United States and had two parts. In the first, 441 adults with obesity took tirzepatide for 60 weeks at 10 or 15 mg, whichever was the highest dose they tolerated. In the second, the 378 who remained were assigned by chance to one of three paths for another 52 weeks, without knowing which: stay on the same dose, drop to 5 mg, or switch to placebo.1

From week 60 to week 112Stayed on 10 or 15 mgStepped down to 5 mgSwitched to placebo
People assigned14014494
Loss from starting weight at week 11221.9%16.6%9.9%
Difference from placebo12.0 points6.6 points—
Share of the full-dose result held100%76%45%
Regained at least half and received rescue8%25%67%

Horn and colleagues, Lancet 2026. The fourth row is our division of each result by 21.9%.

The participants were heavier than in the earlier trials, with an average weight of 113.8 kg (251 lb) and a BMI of 40. Two thirds were women and the average age was 47. Of the 378 people assigned, 345 completed the study.

The authors' conclusion is measured. Continuing the full dose "maintained bodyweight reduction and health-related benefits". Reducing to 5 mg "might provide a valuable alternative to discontinuation, although individuals' treatment response might vary". And for the field as a whole: "long-term treatment is often necessary to maintain bodyweight reduction".1

How the calculator reads the trial

The published result is the loss from the starting weight at week 112 in each group. The calculator turns that into a share of the loss kept. Staying on the full dose kept all of it, by the trial's own description. Stepping down kept 16.6 out of 21.9 points, or 76%. Stopping kept 9.9 out of 21.9, or 45%. Those shares are then applied to the weight you have lost.

That reading rests on one assumption: that the full-dose group was holding steady, so its week-112 result stands for where everyone was at week 60. The trial was built around people who had reached a plateau on their dose, and the authors report that the full dose maintained the reduction, so the assumption is close. It is the reason the page says "trial averages" and not "your forecast".

The three paths for several starting weights

Weight beforeAfter a 21.9% loss lbA year on the full dose lbA year on 5 mg lbA year after stopping lb
200 lb156156167180
250 lb195195209225
300 lb234234250270
350 lb273273292315

Our arithmetic from the trial's week-112 results: 21.9%, 16.6% and 9.9% below the starting weight.

In every row the 5 mg path ends a little under halfway from the full-dose weight to the stopping weight. For a person who started at 250 lb, the choice between the full dose and 5 mg is a difference of about 14 lb a year later, and the choice between 5 mg and stopping is a difference of about 16 lb.

What does the label say about the maintenance dose?

Four sentences in the dosing section cover it.2

The Zepbound label on maintenance
For weight reduction and long-term maintenance5, 10 or 15 mg
For obstructive sleep apnea10 or 15 mg
Maximum for any use15 mg
The 2.5 mg dosestarting only

On how to choose among the three, the label says: "Consider treatment response and tolerability when selecting the maintenance dosage. If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage." On the starter dose it is firm: "The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage."

Three things follow from that wording. There is no single "maintenance dose" that everyone moves to after losing weight. The dose that holds the weight is one of the same three doses that took it off. The label allows a move down to a lower maintenance dose, and it names tolerability as the reason. And 7.5 and 12.5 mg are steps on the way between maintenance doses. The label lists them as increments and does not name them as maintenance doses.

The label also says what the treatment is for. Zepbound is approved "to reduce excess body weight and maintain weight reduction long term". Maintenance is half of the approved purpose, with no end date attached.

What does each maintenance dose deliver?

The main trial assigned people to 5, 10 or 15 mg from the start and kept them there for 72 weeks. The label reports the results for everyone assigned to each dose.2

The three doses, side by sideFDA label
Compare

Main Zepbound trial at week 72, everyone assigned to each dose. Nausea and stopping for side effects are from the pooled two trials in the label.

At week 72Placebo5 mg10 mg15 mg
Average loss3.1%15.0%19.5%20.9%
Lost at least 5%34.5%85.1%88.9%90.9%
Lost at least 10%18.8%68.5%78.1%83.5%
Lost at least 15%8.8%48.0%66.6%70.6%
Lost at least 20%3.1%30.0%50.1%56.7%
Reported nausea8%25%29%28%
Stopped because of side effects3.4%4.8%6.3%6.7%
Stopped because of stomach side effects0.5%1.9%3.3%4.3%

Zepbound label, Tables 1 and 2 and section 6.1.

For a 231 lb starting weight5 mg lb10 mg lb15 mg lb
Average weight at week 72196186183
Average weight at week 176203188185

Our arithmetic from the average losses at week 72 and, for participants with prediabetes, at week 176. The trial's average starting weight was about 231 lb.

The largest step is the first. Going from 5 to 10 mg added 4.5 points of average loss and moved the share who lost a fifth of their weight from 30% to 50%. Going from 10 to 15 mg added 1.4 points and took that share to 57%.

The price of the higher doses shows in the last rows more than in the nausea row. Nausea was reported about as often on all three. The share who gave up treatment over stomach side effects rose with each step, from 1.9% to 3.3% to 4.3%.

So 10 mg is where most of the extra benefit over 5 mg is collected, and 15 mg adds a little more at a little more cost in tolerability. A person who does well on 5 mg is on a maintenance dose in full standing: it is one of the three the label names, and 85 in 100 people assigned to it lost at least 5%. The dosing schedule has each step by date.

How long it takes to reach each dose

Maintenance doseReached, at the fastest paceLevel settled
5 mgweek 4week 8
10 mgweek 12week 16
15 mgweek 20week 24

Label schedule: 2.5 mg for 4 weeks, then steps of 2.5 mg after at least 4 weeks each. The label gives 4 weeks for the level to become steady on a dose.

The dose and the plateau

The dose also sets when the weight stops falling. An analysis of the main trial sorted people by the week their weight levelled off. Among those who levelled off by week 24, 44% were on 5 mg. Among those who were still losing after week 36, 41% were on 15 mg.6 A lower maintenance dose reaches its level sooner, and that level is higher on the scale. The article on the Zepbound plateau goes through that analysis.

A smaller step: 15 mg down to 10 mg

No trial has tested this step in people who had lost their weight on 15 mg. The nearest figures come from people assigned to each dose from the start: 20.9% on 15 mg and 19.5% on 10 mg, a gap of 1.4 points, with 4.3% and 3.3% stopping over stomach side effects.2 On those numbers, the step from 15 to 10 mg looks much smaller than the step from 10 or 15 mg to 5 mg that the trial did test. That is an inference from separate groups, and the label's sentence about tolerability is what permits the move.

Can I step down to a lower dose and keep the weight off?

Most of it, on average, and with a real chance of losing more than that. The step-down trial reports two things about the 5 mg group: where the average ended up, and how many people slid back a long way.

The average first. A year after dropping from 10 or 15 mg to 5 mg, the group stood 16.6% below its starting weight, where the full-dose group stood at 21.9%. About 5 points of body weight had come back, a quarter of the loss. For the trial's average participant that is 13 lb out of 55.1

Then the spread. The trial had a safety valve: from week 84, anyone who had regained more than half of their loss could be given tirzepatide again as "rescue". The share of each group who reached that point shows how often each path went badly.

Who slid back by half or moreLancet 2026
After week 60 they
Regained at least halfDid not

Each dot is one person in a hundred. People who regained at least 50% of their loss and received rescue treatment: 11 of 138, 35 of 142 and 60 of 90.

On the full dose, 8 in 100 regained half or more. On 5 mg it was 25 in 100. On placebo it was 67 in 100. So the lower dose worked for three people in four and failed, by this measure, for one in four. Stopping failed for two in three.

That is the honest shape of the step-down. It is much better than stopping and clearly worse than staying. It suits someone for whom the full dose has a cost, in side effects or in money, that the lower dose reduces. And it calls for a plan for the one-in-four case: a weight at which the dose goes back up.

How the rescue rule worked

The rule is set out in the trial's design paper. From week 84, which is 24 weeks after the groups were split, a participant whose clinic weight showed a regain of 50% or more of the loss achieved by week 60 received rescue treatment. For someone on placebo that meant starting tirzepatide again. For someone on 5 mg it meant a higher dose. It was done without telling participants or staff which group they had been in.8

What counts as holding the loss

The same paper gives three yardsticks that a person can use on their own numbers. A change of 1% to 2% in body weight "is considered a normal physiological fluctuation". A participant who kept at least 80% of the week-60 loss was counted as a maintainer. And a regain of 50% was the point at which the trial stepped in.

The trial's yardsticks, for a 251 lb start and a 196 lb weight on the full dose
Normal fluctuation, 1% to 2% of body weight2 to 4 lb
Still a maintainer: 80% of the 55 lb loss keptup to 207 lb
The rescue point: half of the loss regained224 lb

Between 196 and 200 lb nothing has happened. Up to 207 lb the loss is, by the trial's definition, maintained. The average person on 5 mg ended at 209 lb, just past that line. At 224 lb the trial would have changed the treatment.

What the trial did not test

The step was from 10 or 15 mg straight to 5 mg. The trial did not test 15 to 10 mg, or 10 to 7.5 mg, or any gradual descent. It did not test a step down earlier than week 60, before the weight had levelled off. And everyone in it had been on a high dose first, so it says nothing about someone who lost their weight on 5 mg and wonders about going lower. Below 5 mg there is no maintenance dose in the label.

What if I stop instead?

The placebo group of the same trial answers that: a loss of 21.9% shrank to 9.9% within a year, and two people in three regained more than half. An earlier trial, SURMOUNT-4, found the same from a different starting point. People who stopped after 36 weeks regained 14% on top of their weight over the next year, while those who continued lost a further 5.5%.3

TrialOn the drug for weeksLoss by thenA year after stoppingA year of continuing
SURMOUNT-43620.9%9.9% below the start25.3% below the start
SURMOUNT-MAINTAIN60about 21.9%9.9% below the start21.9% below the start

Aronne and colleagues 2024 and Horn and colleagues 2026. The week-60 loss in the second trial is taken from the full-dose group's result.

Two trials, two lengths of treatment, and the same figure a year after stopping: 9.9% below the starting weight. Staying on the drug for 60 weeks instead of 36 did not protect the loss once the drug was withdrawn. The article on what happens after stopping has the full picture.

Do people keep losing weight on the maintenance dose?

A little, for a while, and then the weight holds. The withdrawal trial shows the first part. People who had lost 20.9% by week 36 and stayed on 10 or 15 mg lost a further 5.5% of their weight over the next year, to end 25.3% below their starting weight. Nine in ten of them, 89.5%, still had at least 80% of their week-36 loss at the end.3

The plateau analysis shows the same tail in the main trial. People whose weight levelled off by week 24 had lost 12.1% at that point and were down 15.4% at week 72. Those who levelled off later went from 24.3% to 26.3%.6 In both groups the loss after the plateau began was two to three points of the starting weight.

Loss before and after the weight levelled off
Levelled off by week 24: then, and at week 7212.1% → 15.4%
Levelled off in weeks 36 to 60: then, and at week 7224.3% → 26.3%

So "maintenance" does not begin with a sharp line. The dose stays the same, the loss slows to a crawl, and over a year or so it stops. Nothing has to be changed for that to happen.

How long does maintenance last?

As long as the treatment does, on the evidence so far. The longest published follow-up is three years. Participants in the main trial who had prediabetes stayed on their assigned dose for 176 weeks.4

Average loss from starting weight5 mg10 mg15 mgPlacebo
Week 72, all participants15.0%19.5%20.9%3.1%
Week 176, participants with prediabetes12.3%18.7%19.7%1.3%

Zepbound label, Table 2, and Jastreboff and colleagues, New England Journal of Medicine 2025.

After three years on the same dose, the average loss was 12.3%, 18.7% and 19.7%. Each is one to three points smaller than the result at week 72, in a somewhat different set of people. The level reached in the second year was, roughly, the level held in the third.

The three doses kept their order over the three years. In the three-year group the gap between 5 mg and 10 mg was 6.4 points, against 4.5 points at week 72. Over a long horizon the choice of maintenance dose matters at least as much as it does at the start.

None of the trials has an arm in which people stopped after reaching a goal and stayed at that weight. The plain reading of the evidence, and of the label's phrase "long term", is that the maintenance dose is taken for as long as the weight is to be kept. In practice many people do not stay that long: in a study of US health records, 64.8% of people without diabetes who started one of these drugs had stopped within a year.5

Does the dose have to go up over the years?

The three-year data do not show that. Participants stayed on the dose they were assigned at the start, with no increases, and the average loss at week 176 was within one to three points of the loss at week 72. A dose that holds the weight in the second year held it, on average, in the third.

Does the maintenance dose also hold the health gains?

The step-down trial's authors say that continuing the full dose maintained "health-related benefits" along with the weight.1 The mirror image comes from the withdrawal trial, where a later analysis followed waist and blood pressure in the people who stopped. The more weight they regained, the more those measures slid back.

A year after stopping, by share of the loss regainedUnder ¼¼ to ½½ to ¾¾ or more
Waist+0.8 cm+5.4 cm+10.1 cm+14.7 cm
Systolic blood pressure+6.8 mm Hg+7.3 mm Hg+9.6 mm Hg+10.4 mm Hg

Horn and colleagues, JAMA Internal Medicine 2026, post hoc analysis of SURMOUNT-4.

For the step-down decision this matters in a practical way. A person on 5 mg who holds three quarters of the loss sits in the first or second column. A person who drifts further moves to the right, and blood pressure is the measure to watch: it rose even in the group that kept most of the weight off once the drug was gone.7

Stopping is often not final. In the same records, 36.3% of the people without diabetes who had stopped were back on one of these drugs within a year, and each 1% of weight regained went with a 2.8% higher rate of restarting.5 For many people long-term treatment in practice is a series of courses with gaps, and the gaps are where the weight returns.

Can I inject every two weeks instead?

The label describes one schedule, once a week, and none of the trials cited here tested a longer interval. So there is no trial result for a dose every 10 or 14 days.

What can be calculated is the level in the body. Tirzepatide has a half-life of about 5 days.2 On weekly dosing, our model puts the low point just before each injection at about 44% of the peak. With the same dose every 14 days, once that schedule has settled, the peak is about 72% of the weekly peak, the level before each dose falls to about 12% of it, and the average level is half of what it was.

Schedule, same doseAverage levelLow point before the next dose
Every 7 days100%about 44% of the weekly peak
Every 14 days, same dose50%about 12% of the weekly peak
Every 14 days, double dose100%about 24% of the weekly peak, after a peak of 143%

Our model with the label's half-life of about 5 days. The average level halves because the same dose is spread over twice the time.

Halving the average level is roughly what halving the dose does, with one difference: the swings are larger. A weekly 5 mg dose and a fortnightly 10 mg dose deliver the same amount of drug, but the first keeps the level between 44% and 100% of its peak, and the second swings between 24% and 143% of that same peak. The trial evidence is for the first. If the aim is less drug, the tested way to get there is a lower weekly dose.

What is different day to day on a stable dose?

Three things ease once the dose stops changing.

Side effects. The label places most nausea, vomiting and diarrhea in the step-up period and says they "decreased over time". The step-down trial reports the same: stomach side effects "mostly occurred during dose escalation".1 A stable dose is the stretch in which they are least likely.

The rule for birth control pills. The label asks pill users for a backup method for 4 weeks after starting and for 4 weeks after each increase. On a dose that is not changing, no new window opens. A later increase opens one again, and so does a move back up after a step down.2

The level in the body. After 4 weeks on the same dose the level is steady, cycling between its weekly peak and about 44% of it. A missed dose breaks that: two weeks after the last injection the level is at 17% of the peak. The label's rule is to take a missed dose within 4 days and otherwise skip it. The article on missed doses has a checker.

Is 5 mg enough as a maintenance dose?

For many people, yes. It is a full maintenance dose in the label, and in the main trial the people assigned to it lost 15.0% on average, with 85 in 100 losing at least 5% and 48 in 100 at least 15%.2

There are two different questions hiding in this one. The first is whether 5 mg is enough to lose the weight. On average it takes off about three quarters of what 15 mg does, 15.0% against 20.9%. A study of when weight loss levels off found that people on 5 mg reached their plateau sooner and at a smaller loss than people on the higher doses.6

The second is whether 5 mg is enough to hold a loss achieved on a higher dose. That is the step-down trial's question, and its answer was 76% of the loss held on average, with one person in four regaining half or more.

A person who reached their result on 5 mg and is stable there has no evidence-based reason to go higher for maintenance. A person who reached a larger loss on 15 mg should expect 5 mg to hold most of it and not all.

When is the dose decision made?

The label ties it to two things, response and tolerability, and both become clear over the first months. Each step up takes at least 4 weeks, so 10 mg is reached no sooner than week 12 and 15 mg no sooner than week 20.

The plateau study gives a sense of the timing on the response side. About half of the participants reached their plateau by week 24 and nearly nine in ten by week 60.6 The step-down trial waited until week 60 before changing anything, by which time most people's weight had stopped moving. A decision about the long-term dose taken before the weight has levelled off is taken without knowing where that dose leads.

The label gives one explicit reason to move down early: "If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage."2

Is the maintenance dose different for sleep apnea?

Yes. For obstructive sleep apnea in adults with obesity, the label's maintenance doses are 10 or 15 mg. The 5 mg dose is not listed for that use.2 The reason is in how the two sleep apnea trials were run: their 469 participants were taken up to the highest dose they tolerated, 10 or 15 mg, and treated for 52 weeks, so those are the doses with results behind them. Someone taking Zepbound for sleep apnea who steps down to 5 mg is below the dose range the label gives for their condition, and that is a point to raise with the prescriber before any change.

What should I settle with my prescriber?

  1. Which dose is my maintenance dose, and why. Response and tolerability are the label's two criteria.
  2. Whether a step down is on the table. The trial figure is 76% of the loss held on 5 mg, with a one-in-four chance of regaining half.
  3. The weight at which the dose goes back up. The trial used a regain of more than half as its trigger. A person can choose an earlier one.
  4. What the drug is prescribed for. For sleep apnea the label's maintenance doses are 10 and 15 mg.
  5. How often to review. Weight, blood pressure and side effects at a set interval.

What can these trials not tell you?

The step-down was one step, at one time. From 10 or 15 mg to 5 mg, at week 60. Other steps and other timings are untested.

One year of follow-up. The step-down groups were followed for 52 weeks. Where the 5 mg group stands after two or three years has not been reported.

Rescue changes the picture. People who regained more than half could go back on the drug from week 84. The main analysis was designed to account for that, by assuming that rescued participants gained no further benefit from their assigned treatment.

The participants were heavy. The average BMI was 40. People who start nearer a BMI of 30 may not behave the same way.

Averages. The spread on 5 mg ran from people who held everything to the one in four who lost half of it.

Only the main results are open. The figures here come from the published summary of the step-down trial. Secondary results the trial planned, such as how many people kept at least 80% of their loss on each path, are in the full paper, which sits behind a paywall.

The maker funded the trials. Both maintenance trials and the three-year follow-up were funded by Eli Lilly.

Short answers to common questions

What is the maintenance dose of Zepbound?

The label names 5, 10 or 15 mg once a week for weight, and 10 or 15 mg for sleep apnea. The choice depends on response and tolerability.

Do I go down to a lower dose once I reach my goal?

The label does not require it. In the trial that tested it, dropping from 10 or 15 mg to 5 mg held 16.6% of a 21.9% loss on average, and one person in four regained half or more.

Can I stay on 2.5 mg?

The label says the 2.5 mg dose is for starting and "is not approved as a maintenance dosage".

Is 7.5 mg or 12.5 mg a maintenance dose?

The label lists them as steps between doses. Its named maintenance doses are 5, 10 and 15 mg.

How long do I stay on the maintenance dose?

The label's purpose is long-term maintenance and names no end. In three-year data the loss held at 12.3%, 18.7% and 19.7% on 5, 10 and 15 mg. In every trial that stopped the drug, weight returned.

Can I take it every other week?

No trial here tested that. On the label's half-life, the level before each fortnightly dose would fall to about 12% of the usual weekly peak. A lower weekly dose is the tested way to take less.

Is the higher dose worth it?

From 5 to 10 mg the average loss rose by 4.5 points. From 10 to 15 mg it rose by 1.4. The share stopping over stomach side effects rose with each step: 1.9%, 3.3% and 4.3%.

What if the weight creeps up on the lower dose?

In the trial, people who regained more than half were put back on the drug. Agreeing a threshold in advance with the prescriber is the practical version of that.

Can I go from 15 mg to 10 mg?

The label allows a lower maintenance dose when the current one is not tolerated, and 10 mg is one of the three it names. No trial has tested that step. People assigned to 10 mg from the start lost 19.5% on average against 20.9% on 15 mg.

Will I keep losing weight on the maintenance dose?

Slowly, at first. People who stayed on 10 or 15 mg after week 36 lost a further 5.5% over the next year. In the three-year data the loss then held.

Does the dose stop working after a few years?

The three-year follow-up kept people on the same dose throughout, and the average loss at week 176 was within one to three points of the loss at week 72.

If I step down and regain, can I go back up?

The label's schedule allows increases of 2.5 mg after at least 4 weeks on a dose, so the way back from 5 mg to 10 mg takes two steps, with at least 4 weeks on 7.5 mg in between. In the trial, people who regained more than half were given the drug again as rescue.

How much regain means the lower dose is not holding?

The trial's design paper treats a change of 1% to 2% of body weight as normal fluctuation and counts anyone who keeps at least 80% of the loss as a maintainer. Its trigger for going back up was a regain of half of the loss. A threshold between those two is a reasonable thing to agree in advance.

Does a lower dose mean fewer side effects?

Fewer people give up over them. In the main trial, 1.9% of people on 5 mg stopped because of stomach side effects, against 3.3% on 10 mg and 4.3% on 15 mg. The share who reported nausea at some point was about the same on all three, 25 to 29 in 100, because most of it happens while the dose is being raised.

How the calculator works

The calculator takes the weight you have lost and multiplies it by the share of the full-dose result that each group in SURMOUNT-MAINTAIN held at week 112: 100% for staying on 10 or 15 mg, 76% for stepping down to 5 mg (16.6 out of 21.9) and 45% for placebo (9.9 out of 21.9). It treats the full-dose group as steady from week 60, which is how the trial's authors describe it. The lines are drawn straight from today to week 52, because the published abstract gives the end result and not the path.

The dots chart rounds the trial's rescue figures, 8%, 25% and 67%, to whole people. The dose chart shows the label's results for everyone assigned to each dose in the main trial. The level figures for a fortnightly schedule come from our one-compartment model with the label's half-life of about 5 days.

Sources

  1. Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2026;407:2305-2318. doi:10.1016/S0140-6736(26)00656-2
  2. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 1, 2.1, 2.2, 6.1, 12.3 and 14.1. accessdata.fda.gov
  3. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331:38-48. doi:10.1001/jama.2023.24945
  4. Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med 2025;392:958-971. doi:10.1056/NEJMoa2410819
  5. Rodriguez PJ, Zhang V, Gratzl S, et al. Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw Open 2025;8:e2457349. doi:10.1001/jamanetworkopen.2024.57349
  6. Horn DB, Kahan S, Batterham RL, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes 2025;15:e12734. doi:10.1111/cob.12734
  7. Horn DB, Linetzky B, Davies MJ, et al. Cardiometabolic parameter change by weight regain on tirzepatide withdrawal in adults with obesity: a post hoc analysis of the SURMOUNT-4 trial. JAMA Intern Med 2026;186:157-167. doi:10.1001/jamainternmed.2025.6112
  8. Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for the maintenance of body weight reduction: rationale, design, and baseline characteristics of SURMOUNT-MAINTAIN. Obesity (Silver Spring) 2025;33:1873-1885. doi:10.1002/oby.70014

Related analyses

Log your weight on the maintenance dose and the app shows the trend.

Open Dose Insider